Company intelligence / Profile preview
Aphios
Woburn, MA, USAaphios.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Developing nanotechnology-enhanced therapeutics and pathogen reduction technologies through multiple subsidiaries, with $44M invested across platforms and $3.9M NIH funding for CFI™[2][5]
- Therapeutic areas
- GastroenterologyPsychiatryOncologyNeurologyInfectious Diseases
- Modalities
- Small moleculesCannabinoids(siRNA)(Therapeutic proteins)(Hydrophobic anticancer drugs)
- Industry
- Biotech
02
Drug pipeline
32 assets31 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Aphios.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aphios.